Correction to: Rim lesions are demonstrated in early relapsing–remitting multiple sclerosis using 3 T‑based susceptibility‑weighted imaging in a multi‑institutional setting

A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing–remitting multiple sclerosis

Therapeutic Advances in Neurological Disorders ◽

10.1177/1756285615572953 ◽

2015 ◽

Vol 8 (2) ◽

pp. 59-70 ◽

Cited By ~ 3

Author(s):

Robert Zivadinov ◽

Michael Dwyer ◽

Silva Markovic-Plese ◽

Brooke Hayward ◽

Niels Bergsland ◽

...

Keyword(s):

Multiple Sclerosis ◽

Gray Matter ◽

Interferon Beta ◽

Susceptibility Weighted Imaging ◽

Relapsing Remitting ◽

Deep Gray Matter ◽

Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing–remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly

Journal of Neuroimmunology ◽

10.1016/j.jneuroim.2015.03.002 ◽

2015 ◽

Vol 281 ◽

pp. 44-50 ◽

Cited By ~ 1

Author(s):

Michael G. Dwyer ◽

Robert Zivadinov ◽

Silva Markovic-Plese ◽

Niels Bergsland ◽

Mari Heininen-Brown ◽

...

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Susceptibility Weighted Imaging ◽

Relapsing Remitting ◽

A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis

Yearbook of Neurology and Neurosurgery ◽

10.1016/j.yneu.2012.04.028 ◽

2012 ◽

Vol 2012 ◽

pp. 70-71

Author(s):

A. Minagar

Keyword(s):

Multiple Sclerosis ◽

Randomized Trial ◽

High Dose ◽

Vitamin D2 ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

High Dose Vitamin

Interferon beta-1b therapy in relapsing-remitting multiple sclerosis: Study design and preliminary results

Electroencephalography and Clinical Neurophysiology ◽

10.1016/s0013-4694(97)88414-7 ◽

1997 ◽

Vol 103 (1) ◽

pp. 99

Author(s):

G Salemi

Keyword(s):

Multiple Sclerosis ◽

Study Design ◽

Interferon Beta ◽

Preliminary Results ◽

Relapsing Remitting ◽

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Yearbook of Neurology and Neurosurgery ◽

10.1016/s0513-5117(09)79049-0 ◽

2009 ◽

Vol 2009 ◽

pp. 99-103

Author(s):

O. Kantarci

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

383 Anti GBM Disease in Association with Alemtuzumab Treatment for Relapsing Remitting Multiple Sclerosis: A Rare Presentation of a Rare Disorder

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2019.03.385 ◽

2019 ◽

Vol 73 (5) ◽

pp. 743-744 ◽

Cited By ~ 1

Keyword(s):

Multiple Sclerosis ◽

Rare Disorder ◽

Rare Presentation ◽

Relapsing Remitting ◽

Effects of relapsing-remitting multiple sclerosis on the stomatognathic system: preliminary findings

Gazzetta Medica Italiana Archivio per le Scienze Mediche ◽

10.23736/s0393-3660.19.04104-4 ◽

2020 ◽

Vol 179 (6) ◽

Author(s):

Gabriel Pádua da Silva ◽

Marcelo Palinkas ◽

Robson F. Tosta Lopes ◽

Saulo C. Vallin Fabrin ◽

Bruno Ferreira ◽

...

Keyword(s):

Multiple Sclerosis ◽

Stomatognathic System ◽

Relapsing Remitting ◽

Induction of Disease Remission With One Cycle of Alemtuzumab in Relapsing Remitting Multiple Sclerosis

10.26226/morressier.59a3eda8d462b8028d895227 ◽

2017 ◽

Author(s):

David E. Klein

Keyword(s):

Multiple Sclerosis ◽

Disease Remission ◽

Relapsing Remitting ◽

Efficacy of Delayed-release Dimethyl Fumarate in Newly Diagnosed Patients With Relapsing-Remitting Multiple Sclerosis: Eight-Year Follow-up of an Integrated Analysis of DEFINE, CONFIRM, and ENDORSE

10.26226/morressier.59a3eda8d462b8028d895222 ◽

2017 ◽

Cited By ~ 1

Author(s):

Ralf Gold

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Integrated Analysis ◽

Newly Diagnosed ◽

Delayed Release ◽

Relapsing Remitting ◽

Changing Disease Modifying Therapy Switching Dynamics for Relapsing-Remitting Multiple Sclerosis Patients

10.26226/morressier.59a3eda8d462b8028d895126 ◽

2017 ◽

Author(s):

Craig Wakeford

Keyword(s):

Multiple Sclerosis ◽

Disease Modifying Therapy ◽

Switching Dynamics ◽

Relapsing Remitting ◽

Disease Modifying ◽

Multiple Sclerosis Patients ◽